Board of Directors
Erica Rose JD
Erica Rose is Director, R&D Compliance, for GlaxoSmithKline, where she has been involved in policy development and, more recently, compliance activities since 1995. Prior to joining GSK’s predecessor, SmithKline Beecham, she was employed at the Congressional Office of Technology Assessment (OTA), working on the Congressional report regarding ethical, legal, economic, and social implications of patenting human DNA. Ms. Rose has a long history of involvement with industry professional societies, including the PABIOTECH Board of Directors, the Greater Philadelphia First-PABIOTECH Life Sciences Task Force, the PhRMA FDA/Biomedical Research Key Issues Team, the BIO Bioethics Committee, and BIO's subcommittees on Biomedical Information and Responsible Uses of Biotechnology. In addition she has been appointed to a diverse group of advisory boards, including the American Bar Association Coordinating Group on Bioethics; the National Conference of State Legislatures Blue Ribbon Panel on genetic technologies; the La Salle University Integrated Science, Business, and Technology Program Advisory Board; the Penn State Nanofabrication Facility Education Advisory Board; the American Association for the Advancement of Science (AAAS) dialogue group on science and religion; and the Hastings Center Working Group on Ethical Issues in the Management of Financial Conflicts of Interest in Biomedical Research. She has authored articles and book chapters on medical information privacy, gene patenting, and financial conflicts of interest in biomedical research, as well as co-authoring several chapters of the biotech reference book Biotechnology: Law, Business, and Regulation (M. Malinowski, ed.).